FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007991289> ?p ?o ?g. }

• W2007991289 endingPage "1939" @default.
• W2007991289 startingPage "1939" @default.
• W2007991289 abstract "Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, CA, USA Abstract: During the menopausal transition, women experience a number of symptoms due to declining estrogen levels, including vasomotor symptoms and vulvar and vaginal atrophy (VVA). Unlike vasomotor symptoms, vaginal dryness and dyspareunia, the main symptoms of VVA, typically worsen without treatment and can significantly impact the quality of life. Up to 60% of postmenopausal women may be affected by VVA, but many women unfortunately do not seek treatment due to embarrassment or other factors. After 20+ years in development, ospemifene (Osphena™) was approved by the US Food and Drug Administration in 2013 for treatment of moderate-to-severe dyspareunia associated with VVA due to menopause. As the first non-hormonal alternative to estrogen-based products for this indication, the approval of ospemifene represents a significant milestone in postmenopausal women’s health. Ospemifene is a non-steroidal estrogen receptor agonist/antagonist, also known as a selective estrogen receptor modulator (SERM), from the same chemical class as the breast cancer drugs tamoxifen and toremifene. Unlike other selective estrogen receptor modulators, ospemifene exerts a strong, nearly full estrogen agonist effect in the vaginal epithelium, making it well suited for the treatment of dyspareunia in postmenopausal women. Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index (decreased parabasal cells and increased superficial cells), decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. Long-term safety studies revealed that 60 mg ospemifene given daily for 52 weeks was well tolerated and was not associated with any endometrium or breast-related safety concerns. This review discusses the preclinical and clinical data supporting the use of ospemifene for the treatment of dyspareunia associated with VVA due to menopause and provides an overview of its clinical safety. Keywords: genitourinary syndrome of menopause, SERM, sexual dysfunction" @default.
• W2007991289 created "2016-06-24" @default.
• W2007991289 creator A5025530600 @default.
• W2007991289 creator A5038173854 @default.
• W2007991289 creator A5061177304 @default.
• W2007991289 date "2014-11-01" @default.
• W2007991289 modified "2023-09-25" @default.
• W2007991289 title "Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause" @default.
• W2007991289 cites W1586699954 @default.
• W2007991289 cites W1593442063 @default.
• W2007991289 cites W1963570942 @default.
• W2007991289 cites W1963820278 @default.
• W2007991289 cites W1965726545 @default.
• W2007991289 cites W1969487403 @default.
• W2007991289 cites W1972095294 @default.
• W2007991289 cites W1981922048 @default.
• W2007991289 cites W1982521833 @default.
• W2007991289 cites W1984565138 @default.
• W2007991289 cites W1984670037 @default.
• W2007991289 cites W1984925799 @default.
• W2007991289 cites W1988443422 @default.
• W2007991289 cites W1989239843 @default.
• W2007991289 cites W1995584214 @default.
• W2007991289 cites W1997279492 @default.
• W2007991289 cites W1997883187 @default.
• W2007991289 cites W2001507203 @default.
• W2007991289 cites W2008549740 @default.
• W2007991289 cites W2009439253 @default.
• W2007991289 cites W2011732209 @default.
• W2007991289 cites W2011779669 @default.
• W2007991289 cites W2013230144 @default.
• W2007991289 cites W2028480034 @default.
• W2007991289 cites W2032958881 @default.
• W2007991289 cites W2041938813 @default.
• W2007991289 cites W2042041115 @default.
• W2007991289 cites W2058475235 @default.
• W2007991289 cites W2070506018 @default.
• W2007991289 cites W2073139329 @default.
• W2007991289 cites W2074344979 @default.
• W2007991289 cites W2079795132 @default.
• W2007991289 cites W2081111891 @default.
• W2007991289 cites W2085509695 @default.
• W2007991289 cites W2089322530 @default.
• W2007991289 cites W2096913799 @default.
• W2007991289 cites W2112629831 @default.
• W2007991289 cites W2124816391 @default.
• W2007991289 cites W2130825104 @default.
• W2007991289 cites W2133813353 @default.
• W2007991289 cites W2139272277 @default.
• W2007991289 cites W2154460676 @default.
• W2007991289 cites W2157527217 @default.
• W2007991289 cites W2165198403 @default.
• W2007991289 cites W2166871891 @default.
• W2007991289 cites W2317078969 @default.
• W2007991289 cites W4210972163 @default.
• W2007991289 cites W4235178597 @default.
• W2007991289 cites W4244853583 @default.
• W2007991289 doi "https://doi.org/10.2147/cia.s73753" @default.
• W2007991289 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4235480" @default.
• W2007991289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25419123" @default.
• W2007991289 hasPublicationYear "2014" @default.
• W2007991289 type Work @default.
• W2007991289 sameAs 2007991289 @default.
• W2007991289 citedByCount "18" @default.
• W2007991289 countsByYear W20079912892015 @default.
• W2007991289 countsByYear W20079912892017 @default.
• W2007991289 countsByYear W20079912892018 @default.
• W2007991289 countsByYear W20079912892019 @default.
• W2007991289 countsByYear W20079912892020 @default.
• W2007991289 countsByYear W20079912892022 @default.
• W2007991289 crossrefType "journal-article" @default.
• W2007991289 hasAuthorship W2007991289A5025530600 @default.
• W2007991289 hasAuthorship W2007991289A5038173854 @default.
• W2007991289 hasAuthorship W2007991289A5061177304 @default.
• W2007991289 hasBestOaLocation W20079912891 @default.
• W2007991289 hasConcept C121608353 @default.
• W2007991289 hasConcept C126322002 @default.
• W2007991289 hasConcept C143998085 @default.
• W2007991289 hasConcept C2776917545 @default.
• W2007991289 hasConcept C2777164284 @default.
• W2007991289 hasConcept C2777176818 @default.
• W2007991289 hasConcept C2777637070 @default.
• W2007991289 hasConcept C2777944059 @default.
• W2007991289 hasConcept C2778562196 @default.
• W2007991289 hasConcept C29456083 @default.
• W2007991289 hasConcept C530470458 @default.
• W2007991289 hasConcept C71924100 @default.
• W2007991289 hasConceptScore W2007991289C121608353 @default.
• W2007991289 hasConceptScore W2007991289C126322002 @default.
• W2007991289 hasConceptScore W2007991289C143998085 @default.
• W2007991289 hasConceptScore W2007991289C2776917545 @default.
• W2007991289 hasConceptScore W2007991289C2777164284 @default.
• W2007991289 hasConceptScore W2007991289C2777176818 @default.
• W2007991289 hasConceptScore W2007991289C2777637070 @default.
• W2007991289 hasConceptScore W2007991289C2777944059 @default.
• W2007991289 hasConceptScore W2007991289C2778562196 @default.
• W2007991289 hasConceptScore W2007991289C29456083 @default.
• W2007991289 hasConceptScore W2007991289C530470458 @default.

• next